Absorption and drug development : solubility, permeability, and charge state / Alex Avdeef
| Medienart: |
Buch |
|---|
| Erscheinungsjahr: |
[2012] ©2012 |
|---|---|
| Erschienen: |
Hoboken, NJ: Wiley ; 2012 ©2012 |
| Ausgabe: |
Second edition |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Avdeef, Alex [VerfasserIn] |
|---|
| Links: |
|---|
| ISBN: |
|---|
| RVK: |
|---|
| Anmerkungen: |
Literaturangaben und Index |
|---|
| Umfang: |
XLI, 698 Seiten ; Illustrationen, Diagramme |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
671729462 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 671729462 | ||
| 003 | DE-627 | ||
| 005 | 20230905072235.0 | ||
| 007 | tu | ||
| 008 | 111108s2012 xxu||||| 00| ||eng c | ||
| 010 | |a 2011044252 | ||
| 020 | |a 9781118057452 |c cloth |9 978-1-118-05745-2 | ||
| 035 | |a (DE-627)671729462 | ||
| 035 | |a (DE-599)GBV671729462 | ||
| 035 | |a (OCoLC)805850114 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XD-US | ||
| 050 | 0 | |a RS420 | |
| 060 | 0 | |a QV 38 | |
| 082 | 0 | |a 615/.19 |q LOC |2 23 | |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a VS 5352 |q OBV |2 rvk |0 (DE-625)rvk/147687:255 | ||
| 084 | |a VX 8550 |q BVB |2 rvk |0 (DE-625)rvk/147830:253 | ||
| 084 | |a 58.28 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Avdeef, Alex |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Absorption and drug development |b solubility, permeability, and charge state |c Alex Avdeef |
| 250 | |a Second edition | ||
| 263 | |a 1206 | ||
| 264 | 1 | |a Hoboken, NJ |b Wiley |c [2012] | |
| 264 | 4 | |c ©2012 | |
| 300 | |a XLI, 698 Seiten |b Illustrationen, Diagramme | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Literaturangaben und Index | ||
| 505 | 8 | 0 | |a Introduction -- Transport model -- pKa determination -- Octanol-water partitioning -- Liposome-water partitioning -- Solubility -- Permeability - Pampa -- Permeability Caco 2/MDCK -- Permeability blood brain barrier. |
| 650 | 2 | |a Pharmaceutical Preparations |x metabolism | |
| 650 | 2 | |a Administration, Oral | |
| 650 | 2 | |a Cell Membrane Permeability | |
| 650 | 2 | |a Pharmaceutical Preparations |x chemistry | |
| 650 | 2 | |a Structure-Activity Relationship | |
| 653 | 4 | |a Absorption. | |
| 653 | 4 | |a Drugs--Analysis. | |
| 689 | 0 | 0 | |D s |0 (DE-588)4003116-0 |0 (DE-627)104791799 |0 (DE-576)208850333 |a Arzneimittelanalyse |2 gnd |
| 689 | 0 | 1 | |D s |0 (DE-588)4000245-7 |0 (DE-627)106401742 |0 (DE-576)20883740X |a Absorption |2 gnd |
| 689 | 0 | 2 | |D s |0 (DE-588)4143176-5 |0 (DE-627)104408812 |0 (DE-576)209724234 |a Arzneimittelentwicklung |2 gnd |
| 689 | 0 | |5 (DE-627) | |
| 856 | 4 | 2 | |u http://www.gbv.de/dms/bs/toc/671729462.pdf |m V:DE-601 |m B:DE-84 |q pdf/application |v 2012-07-16 |x Verlag |y Inhaltsverzeichnis |3 Inhaltsverzeichnis |
| 912 | |a GBV_ILN_20 | ||
| 912 | |a ISIL_DE-84 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a ISIL_DE-3 | ||
| 912 | |a GBV_ILN_65_a004 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a ISIL_DE-9 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a ISIL_DE-Hil2 | ||
| 936 | r | v | |a VS 5352 |b Kompendien, Repetitorien, Leitfäden, Kurzdarstellungen und Vorlesungsskripten |k Chemie und Pharmazie |k Pharmazeutische Chemie und Molekularpharmakologie |k Pharmazeutische Chemie und Molekularpharmakologie allgemein |k Arzneimittelsynthese Arzneimittelentwicklung Struktur-Aktivitäts-Beziehung |k Kompendien, Repetitorien, Leitfäden, Kurzdarstellungen und Vorlesungsskripten |0 (DE-627)127665202X |0 (DE-625)rvk/147687:255 |0 (DE-576)20665202X |
| 936 | r | v | |a VX 8550 |b Allgemeines |k Chemie und Pharmazie |k Pharmazeutische Technologie einschl. Biopharmazie |k Pharmazeutische Technologie allgemein |k Pharmakokinetik |k Allgemeines |0 (DE-627)1271728699 |0 (DE-625)rvk/147830:253 |0 (DE-576)201728699 |
| 936 | b | k | |a 58.28 |j Pharmazeutische Technologie |0 (DE-627)106417622 |
| 936 | b | k | |a 44.38 |j Pharmakologie |0 (DE-627)106409743 |
| 951 | |a BO | ||
| 953 | |2 045F |a 615/.19 | ||
| 980 | |2 20 |1 01 |x 0084 |b 129184452X |c 00 |f LS2 |d PM C 768 |e --%%-- |j --%%-- |c 09 |f --%%-- |d 2922-3347 |e --%%-- |j --%%-- |y k |z 26-06-12 | ||
| 980 | |2 65 |1 01 |x 3/4 |b 3520566915 |c 00 |f Ha 4 |d VX 8550 166<2> |e u |j --%%-- |y ka004 |z 25-10-19 | ||
| 980 | |2 69 |1 01 |x 0009 |b 1313263818 |c 00 |f UB 660 |d 660/VS 5350 A947(2) |e u |j --%%-- |y z |z 17-08-12 | ||
| 980 | |2 90 |1 01 |x 3090 |b 1712970631 |c 00 |f --%%-- |d CHE 635 : A78 |e u |j --%%-- |y z |z 27-10-17 | ||
| 983 | |2 69 |1 00 |x DE-9 |8 00 |a VS 5350 | ||
| 983 | |2 90 |1 00 |x DE-Hil2 |8 00 |a CHE 635 | ||
| 984 | |2 20 |1 01 |x 0084 |a 84$029223347 | ||
| 984 | |2 65 |1 01 |x 3/4 |a 3/15$000486868 | ||
| 984 | |2 69 |1 01 |x 0009 |a 9$09347607 | ||
| 984 | |2 90 |1 01 |x 3090 |a HIL2$05152259 | ||
| 985 | |2 65 |1 01 |x 3/4 |a 4/2019/01077 | ||
| 985 | |2 69 |1 01 |x 0009 |a 2012.8141 | ||
| 985 | |2 90 |1 01 |x 3090 |a 17:09383 | ||